Emerging Companies

June 23, 2014

The Jumpstart Our Business Startup (JOBS) Act marks a key departure from the previous one-size...

January 24, 2014

Ron Cohen MD, President and Chief Executive Officer, Acorda Therapeutics, Inc., discusses what...

October 25, 2013

BIO featured Jan Lundberg of Eli Lilly as this year's fireside chat speaker at the BIO...

October 25, 2013

Stephan Tanda, Managing Board Member with Royal DSM, discusses what is necessary to create an...

Letters, Testimony & Comments

April 30 2015
On behalf of the Biotechnology Industry Organization Before the United States House of Representatives Committee on Financial Services, Subcommittee on Capital Markets and Government Sponsored Enterprises --- Legislative Proposals to Enhance Capital Formation and Reduce Regulatory Burdens
April 29 2014
Chairperson Mikulski, Ranking Member Shelby, Members of the Committee, thank you for the opportunity to provide you with written testimony on the extremely important topic of driving innovation through federal investments.
November 6 2013
On behalf of the BIO and its 1,100 members, I am writing in strong support of your Start-up Jobs and Innovation Act. I want to thank you for introducing this important legislation, which will spur investment in small biotech companies and other innovative businesses.
July 10 2013
A healthy public market is key to the success of the biotech industry, as growing innovators often turn to an IPO to fund late-stage clinical trials.
July 26 2012
Jeffrey S. Hatfield, President and Chief Executive Officer of Vitae Pharmaceuticals, testified on behalf of BIO about the 10th anniversary of the Sarbanes-Oxley Act.

Press Releases

August 11 2015
BIO Investor Forum to be held October 20-21 in San Francisco, California  
June 11 2015
BIO released a new report - Emerging Therapeutic Company Investment and Deal Trends – highlighting ten years (2005-2014) of biotechnology funding and deal making across five areas: venture capital, IPOs, follow-on public offerings, licensing, and acquisitions. The report also offers a first-time look at the degree of collaboration across the industry’s clinical pipeline.
May 21 2015
By making this tax credit permanent, companies conducting their development programs will be able to estimate their tax liability and will not be burdened by the constant uncertainty regarding whether or not the R&D Tax Credit will be extended.
May 13 2015
By teaming up with Aon, we are able to offer our members state-of-the-art coverage enhancements specific for life sciences companies...
May 7 2015
Program will improve liquidity and enhance capital formation for emerging biotech companies